TP53 and B-cell chronic lymphocytic leukemia: Importantly, the PIM inhibitor did not affect the viability of normal B lymphocytes and was equally effective in triggering apoptosis in CLL cells from patients with 17p/TP53 abnormalities as in TP53 wild‐type cells.